Compare GKOS & BTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | BTG |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.3B |
| IPO Year | 2015 | 2007 |
| Metric | GKOS | BTG |
|---|---|---|
| Price | $102.43 | $4.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 2 |
| Target Price | ★ $126.92 | $6.00 |
| AVG Volume (30 Days) | 1.0M | ★ 23.7M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.86% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $507,442,000.00 | N/A |
| Revenue This Year | $23.32 | $38.08 |
| Revenue Next Year | $27.43 | $28.46 |
| P/E Ratio | ★ N/A | $34.75 |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $73.16 | $3.31 |
| 52 Week High | $148.11 | $6.29 |
| Indicator | GKOS | BTG |
|---|---|---|
| Relative Strength Index (RSI) | 28.38 | 48.83 |
| Support Level | $92.38 | $4.23 |
| Resistance Level | $102.80 | $4.99 |
| Average True Range (ATR) | 7.36 | 0.20 |
| MACD | -4.94 | -0.03 |
| Stochastic Oscillator | 1.08 | 25.32 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.